Annual Operating Profit
$4.23 B
-$760.80 M-15.23%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual operaing income is currently $4.23 billion, with the most recent change of -$760.80 million (-15.23%) on 31 December 2023. During the last 3 years, it has risen by +$656.60 million (+18.36%). REGN annual operating profit is now -52.94% below its all-time high of $8.99 billion, reached on 31 December 2021.REGN Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
$1.24 B
+$142.20 M+13.00%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly operating income is currently $1.24 billion, with the most recent change of +$142.20 million (+13.00%) on 30 September 2024. Over the past year, it has increased by +$24.70 million (+2.04%). REGN quarterly operating profit is now -63.08% below its all-time high of $3.35 billion, reached on 30 June 2021.REGN Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
$4.09 B
+$24.70 M+0.61%
30 September 2024
Summary:
Regeneron Pharmaceuticals TTM operating income is currently $4.09 billion, with the most recent change of +$24.70 million (+0.61%) on 30 September 2024. Over the past year, it has dropped by -$316.50 million (-7.18%). REGN TTM operating profit is now -55.39% below its all-time high of $9.17 billion, reached on 31 March 2022.REGN TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -15.2% | +2.0% | -7.2% |
| 3 y3 years | +18.4% | -33.1% | -45.3% |
| 5 y5 years | +67.0% | +67.3% | +81.6% |
REGN Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -52.9% | +18.4% | -54.0% | +62.9% | -55.4% | +2.5% |
| 5 y | 5 years | -52.9% | +91.6% | -63.1% | +88.3% | -55.4% | +85.1% |
| alltime | all time | -52.9% | +2163.4% | -63.1% | +2148.6% | -55.4% | +2093.9% |
Regeneron Pharmaceuticals Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.24 B(+13.0%) | $4.09 B(+0.6%) |
| June 2024 | - | $1.09 B(+44.2%) | $4.07 B(+1.9%) |
| Mar 2024 | - | $758.50 M(-24.4%) | $3.99 B(-5.8%) |
| Dec 2023 | $4.23 B(-15.2%) | $1.00 B(-17.2%) | $4.23 B(-3.9%) |
| Sept 2023 | - | $1.21 B(+19.1%) | $4.41 B(-0.3%) |
| June 2023 | - | $1.02 B(+1.4%) | $4.42 B(-6.2%) |
| Mar 2023 | - | $1.00 B(-14.8%) | $4.71 B(-5.7%) |
| Dec 2022 | $4.99 B(-44.5%) | $1.18 B(-3.8%) | $4.99 B(-23.2%) |
| Sept 2022 | - | $1.22 B(-6.4%) | $6.50 B(-8.7%) |
| June 2022 | - | $1.31 B(+1.6%) | $7.13 B(-22.3%) |
| Mar 2022 | - | $1.29 B(-52.1%) | $9.17 B(+1.9%) |
| Dec 2021 | $8.99 B(+151.5%) | $2.69 B(+45.5%) | $8.99 B(+20.3%) |
| Sept 2021 | - | $1.85 B(-44.8%) | $7.47 B(+11.9%) |
| June 2021 | - | $3.35 B(+200.8%) | $6.68 B(+67.5%) |
| Mar 2021 | - | $1.11 B(-4.7%) | $3.99 B(+11.5%) |
| Dec 2020 | $3.58 B(+61.9%) | $1.17 B(+10.8%) | $3.58 B(+15.9%) |
| Sept 2020 | - | $1.05 B(+60.4%) | $3.09 B(+11.4%) |
| June 2020 | - | $656.40 M(-6.2%) | $2.77 B(+14.0%) |
| Mar 2020 | - | $700.10 M(+3.6%) | $2.43 B(+10.0%) |
| Dec 2019 | $2.21 B(-12.8%) | $675.70 M(-8.5%) | $2.21 B(-1.9%) |
| Sept 2019 | - | $738.50 M(+134.0%) | $2.25 B(+5.2%) |
| June 2019 | - | $315.60 M(-34.3%) | $2.14 B(-12.5%) |
| Mar 2019 | - | $480.00 M(-33.2%) | $2.45 B(-3.4%) |
| Dec 2018 | $2.53 B(+21.9%) | $718.10 M(+14.5%) | $2.53 B(+7.6%) |
| Sept 2018 | - | $626.90 M(+0.8%) | $2.36 B(+2.9%) |
| June 2018 | - | $622.20 M(+9.7%) | $2.29 B(+3.2%) |
| Mar 2018 | - | $567.20 M(+5.3%) | $2.22 B(+6.6%) |
| Dec 2017 | $2.08 B(+56.3%) | $538.82 M(-3.8%) | $2.08 B(+10.2%) |
| Sept 2017 | - | $559.93 M(+1.7%) | $1.89 B(+11.7%) |
| June 2017 | - | $550.31 M(+27.8%) | $1.69 B(+18.1%) |
| Mar 2017 | - | $430.54 M(+24.1%) | $1.43 B(+7.6%) |
| Dec 2016 | $1.33 B(+6.3%) | $346.96 M(-4.4%) | $1.33 B(+9.5%) |
| Sept 2016 | - | $362.80 M(+24.4%) | $1.21 B(-2.4%) |
| June 2016 | - | $291.63 M(-11.4%) | $1.24 B(-4.1%) |
| Mar 2016 | - | $329.31 M(+42.5%) | $1.30 B(+3.7%) |
| Dec 2015 | $1.25 B(+51.9%) | $231.08 M(-41.1%) | $1.25 B(+1.2%) |
| Sept 2015 | - | $392.42 M(+13.8%) | $1.24 B(+19.8%) |
| June 2015 | - | $344.86 M(+21.6%) | $1.03 B(+12.7%) |
| Mar 2015 | - | $283.55 M(+31.4%) | $915.91 M(+11.2%) |
| Dec 2014 | $823.92 M(+10.9%) | $215.80 M(+14.5%) | $823.92 M(+2.6%) |
| Sept 2014 | - | $188.46 M(-17.4%) | $803.21 M(-5.7%) |
| June 2014 | - | $228.09 M(+19.1%) | $851.55 M(+9.0%) |
| Mar 2014 | - | $191.56 M(-1.8%) | $781.56 M(+5.2%) |
| Dec 2013 | $743.05 M(+62.3%) | $195.09 M(-17.6%) | $743.05 M(+7.1%) |
| Sept 2013 | - | $236.80 M(+49.8%) | $693.63 M(+5.2%) |
| June 2013 | - | $158.10 M(+3.3%) | $659.19 M(+12.0%) |
| Mar 2013 | - | $153.05 M(+5.1%) | $588.56 M(+28.6%) |
| Dec 2012 | $457.71 M(-323.1%) | $145.67 M(-28.0%) | $457.71 M(+71.7%) |
| Sept 2012 | - | $202.36 M(+131.3%) | $266.64 M(+4481.5%) |
| June 2012 | - | $87.48 M(+294.0%) | $5.82 M(-104.1%) |
| Mar 2012 | - | $22.20 M(-148.9%) | -$141.98 M(-30.8%) |
| Dec 2011 | -$205.16 M(+110.5%) | -$45.40 M(-22.3%) | -$205.16 M(+18.9%) |
| Sept 2011 | - | -$58.46 M(-3.1%) | -$172.53 M(+18.0%) |
| June 2011 | - | -$60.32 M(+47.2%) | -$146.17 M(+33.4%) |
| Mar 2011 | - | -$40.98 M(+220.7%) | -$109.58 M(+12.4%) |
| Dec 2010 | -$97.47 M(+31.5%) | -$12.78 M(-60.2%) | -$97.47 M(-21.5%) |
| Sept 2010 | - | -$32.09 M(+35.3%) | -$124.10 M(+33.0%) |
| June 2010 | - | -$23.72 M(-17.8%) | -$93.30 M(+8.7%) |
| Mar 2010 | - | -$28.88 M(-26.7%) | -$85.84 M(+15.8%) |
| Dec 2009 | -$74.10 M(-14.1%) | -$39.41 M(+2952.5%) | -$74.10 M(+12.8%) |
| Sept 2009 | - | -$1.29 M(-92.1%) | -$65.71 M(-22.1%) |
| June 2009 | - | -$16.27 M(-5.1%) | -$84.35 M(-3.8%) |
| Mar 2009 | - | -$17.14 M(-44.7%) | -$87.71 M(+1.4%) |
| Dec 2008 | -$86.25 M(-24.6%) | -$31.02 M(+55.6%) | -$86.48 M(+29.1%) |
| Sept 2008 | - | -$19.93 M(+1.6%) | -$67.00 M(-21.9%) |
| June 2008 | - | -$19.62 M(+23.3%) | -$85.73 M(-11.4%) |
| Mar 2008 | - | -$15.91 M(+37.9%) | -$96.72 M(-15.5%) |
| Dec 2007 | -$114.45 M | -$11.53 M(-70.2%) | -$114.45 M(-16.1%) |
| Sept 2007 | - | -$38.67 M(+26.3%) | -$136.41 M(+8.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2007 | - | -$30.60 M(-9.0%) | -$126.00 M(+5.3%) |
| Mar 2007 | - | -$33.65 M(+0.5%) | -$119.64 M(+11.1%) |
| Dec 2006 | -$107.66 M(-186.5%) | -$33.49 M(+18.5%) | -$107.66 M(-174.2%) |
| Sept 2006 | - | -$28.26 M(+16.5%) | $145.15 M(+4.4%) |
| June 2006 | - | -$24.25 M(+11.9%) | $139.02 M(+6.0%) |
| Mar 2006 | - | -$21.66 M(-109.9%) | $131.10 M(+5.4%) |
| Dec 2005 | $124.42 M(+2103.7%) | $219.31 M(-737.8%) | $124.42 M(-236.8%) |
| Sept 2005 | - | -$34.39 M(+6.9%) | -$90.92 M(+37.7%) |
| June 2005 | - | -$32.17 M(+13.5%) | -$66.01 M(+42.0%) |
| Mar 2005 | - | -$28.34 M(-813.1%) | -$46.49 M(-923.4%) |
| Dec 2004 | $5.65 M(-105.6%) | $3.97 M(-141.9%) | $5.65 M(-136.5%) |
| Sept 2004 | - | -$9.48 M(-25.0%) | -$15.47 M(-51.2%) |
| June 2004 | - | -$12.64 M(-153.1%) | -$31.69 M(-33.4%) |
| Mar 2004 | - | $23.79 M(-238.8%) | -$47.60 M(-52.3%) |
| Dec 2003 | -$99.99 M(-18.0%) | -$17.14 M(-33.3%) | -$99.78 M(-14.9%) |
| Sept 2003 | - | -$25.70 M(-10.0%) | -$117.27 M(-5.2%) |
| June 2003 | - | -$28.56 M(+0.6%) | -$123.74 M(-1.1%) |
| Mar 2003 | - | -$28.38 M(-18.1%) | -$125.14 M(+2.6%) |
| Dec 2002 | -$121.95 M(+42.3%) | -$34.63 M(+7.6%) | -$121.95 M(+4.3%) |
| Sept 2002 | - | -$32.18 M(+7.4%) | -$116.91 M(+8.2%) |
| June 2002 | - | -$29.95 M(+18.9%) | -$108.03 M(+12.3%) |
| Mar 2002 | - | -$25.19 M(-14.9%) | -$96.17 M(+12.2%) |
| Dec 2001 | -$85.68 M(+239.0%) | -$29.59 M(+27.0%) | -$85.68 M(+30.1%) |
| Sept 2001 | - | -$23.29 M(+28.8%) | -$65.88 M(+13.4%) |
| June 2001 | - | -$18.09 M(+22.9%) | -$58.07 M(+32.4%) |
| Mar 2001 | - | -$14.71 M(+50.3%) | -$43.87 M(+16.6%) |
| Dec 2000 | -$25.28 M(+6.2%) | -$9.79 M(-36.8%) | -$37.64 M(+31.8%) |
| Sept 2000 | - | -$15.49 M(+298.9%) | -$28.55 M(+57.2%) |
| June 2000 | - | -$3.88 M(-54.2%) | -$18.16 M(-19.9%) |
| Mar 2000 | - | -$8.48 M(+1111.4%) | -$22.68 M(-7.8%) |
| Dec 1999 | -$23.80 M(+90.4%) | -$700.00 K(-86.3%) | -$24.60 M(-17.7%) |
| Sept 1999 | - | -$5.10 M(-39.3%) | -$29.90 M(+9.9%) |
| June 1999 | - | -$8.40 M(-19.2%) | -$27.20 M(+50.3%) |
| Mar 1999 | - | -$10.40 M(+73.3%) | -$18.10 M(+43.7%) |
| Dec 1998 | -$12.50 M(-8.8%) | -$6.00 M(+150.0%) | -$12.60 M(+8.6%) |
| Sept 1998 | - | -$2.40 M(-442.9%) | -$11.60 M(+12.6%) |
| June 1998 | - | $700.00 K(-114.3%) | -$10.30 M(-29.9%) |
| Mar 1998 | - | -$4.90 M(-2.0%) | -$14.70 M(+5.8%) |
| Dec 1997 | -$13.70 M(-20.8%) | -$5.00 M(+354.5%) | -$13.90 M(+3.7%) |
| Sept 1997 | - | -$1.10 M(-70.3%) | -$13.40 M(-19.8%) |
| June 1997 | - | -$3.70 M(-9.8%) | -$16.70 M(0.0%) |
| Mar 1997 | - | -$4.10 M(-8.9%) | -$16.70 M(-3.5%) |
| Dec 1996 | -$17.30 M(+127.6%) | -$4.50 M(+2.3%) | -$17.30 M(+11.6%) |
| Sept 1996 | - | -$4.40 M(+18.9%) | -$15.50 M(+14.8%) |
| June 1996 | - | -$3.70 M(-21.3%) | -$13.50 M(+21.6%) |
| Mar 1996 | - | -$4.70 M(+74.1%) | -$11.10 M(+30.6%) |
| Dec 1995 | -$7.60 M(-74.0%) | -$2.70 M(+12.5%) | -$8.50 M(-22.0%) |
| Sept 1995 | - | -$2.40 M(+84.6%) | -$10.90 M(-10.7%) |
| June 1995 | - | -$1.30 M(-38.1%) | -$12.20 M(-41.6%) |
| Mar 1995 | - | -$2.10 M(-58.8%) | -$20.90 M(-28.4%) |
| Dec 1994 | -$29.20 M(-24.7%) | -$5.10 M(+37.8%) | -$29.20 M(-17.3%) |
| Sept 1994 | - | -$3.70 M(-63.0%) | -$35.30 M(-13.7%) |
| June 1994 | - | -$10.00 M(-3.8%) | -$40.90 M(+0.5%) |
| Mar 1994 | - | -$10.40 M(-7.1%) | -$40.70 M(+3.0%) |
| Dec 1993 | -$38.80 M(+112.0%) | -$11.20 M(+20.4%) | -$39.50 M(+14.8%) |
| Sept 1993 | - | -$9.30 M(-5.1%) | -$34.40 M(+12.1%) |
| June 1993 | - | -$9.80 M(+6.5%) | -$30.70 M(+25.8%) |
| Mar 1993 | - | -$9.20 M(+50.8%) | -$24.40 M(+32.6%) |
| Dec 1992 | -$18.30 M(+90.6%) | -$6.10 M(+8.9%) | -$18.40 M(+15.0%) |
| Sept 1992 | - | -$5.60 M(+60.0%) | -$16.00 M(+24.0%) |
| June 1992 | - | -$3.50 M(+9.4%) | -$12.90 M(+13.2%) |
| Mar 1992 | - | -$3.20 M(-13.5%) | -$11.40 M(+83.9%) |
| Dec 1991 | -$9.60 M(+190.9%) | -$3.70 M(+48.0%) | -$6.20 M(-34.7%) |
| Sept 1991 | - | -$2.50 M(+25.0%) | -$9.50 M(+66.7%) |
| June 1991 | - | -$2.00 M(-200.0%) | -$5.70 M(+128.0%) |
| Mar 1991 | - | $2.00 M(-128.6%) | -$2.50 M(-24.2%) |
| Dec 1990 | -$3.30 M | -$7.00 M(-638.5%) | -$3.30 M(-189.2%) |
| Sept 1990 | - | $1.30 M(+8.3%) | $3.70 M(+54.2%) |
| June 1990 | - | $1.20 M(0.0%) | $2.40 M(+100.0%) |
| Mar 1990 | - | $1.20 M | $1.20 M |
FAQ
- What is Regeneron Pharmaceuticals annual operaing income?
- What is the all time high annual operating profit for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual operating profit year-on-year change?
- What is Regeneron Pharmaceuticals quarterly operating income?
- What is the all time high quarterly operating profit for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly operating profit year-on-year change?
- What is Regeneron Pharmaceuticals TTM operating income?
- What is the all time high TTM operating profit for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM operating profit year-on-year change?
What is Regeneron Pharmaceuticals annual operaing income?
The current annual operating profit of REGN is $4.23 B
What is the all time high annual operating profit for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual operaing income is $8.99 B
What is Regeneron Pharmaceuticals annual operating profit year-on-year change?
Over the past year, REGN annual operaing income has changed by -$760.80 M (-15.23%)
What is Regeneron Pharmaceuticals quarterly operating income?
The current quarterly operating profit of REGN is $1.24 B
What is the all time high quarterly operating profit for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly operating income is $3.35 B
What is Regeneron Pharmaceuticals quarterly operating profit year-on-year change?
Over the past year, REGN quarterly operating income has changed by +$24.70 M (+2.04%)
What is Regeneron Pharmaceuticals TTM operating income?
The current TTM operating profit of REGN is $4.09 B
What is the all time high TTM operating profit for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM operating income is $9.17 B
What is Regeneron Pharmaceuticals TTM operating profit year-on-year change?
Over the past year, REGN TTM operating income has changed by -$316.50 M (-7.18%)